DK3377109T3 - Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum - Google Patents

Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum Download PDF

Info

Publication number
DK3377109T3
DK3377109T3 DK16801984.2T DK16801984T DK3377109T3 DK 3377109 T3 DK3377109 T3 DK 3377109T3 DK 16801984 T DK16801984 T DK 16801984T DK 3377109 T3 DK3377109 T3 DK 3377109T3
Authority
DK
Denmark
Prior art keywords
anticholinergic
corticosteroid
adrenergic
beta
preparation
Prior art date
Application number
DK16801984.2T
Other languages
English (en)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3377109(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Application granted granted Critical
Publication of DK3377109T3 publication Critical patent/DK3377109T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16801984.2T 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum DK3377109T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16
PCT/EP2016/077566 WO2017085007A1 (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Publications (1)

Publication Number Publication Date
DK3377109T3 true DK3377109T3 (da) 2020-04-20

Family

ID=54548063

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20156815.1T DK3689379T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DK16801984.2T DK3377109T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering, som omfatter anticholinergikum, corticosteroid og beta-adrenergikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20156815.1T DK3689379T3 (da) 2015-11-16 2016-11-14 Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum

Country Status (31)

Country Link
US (3) US10086003B2 (da)
EP (2) EP3689379B1 (da)
JP (1) JP6942126B2 (da)
KR (1) KR20180082442A (da)
CN (1) CN108348614B (da)
AR (1) AR106687A1 (da)
AU (1) AU2016357988B2 (da)
CA (1) CA3005291C (da)
CL (1) CL2018001297A1 (da)
CO (1) CO2018005139A2 (da)
DK (2) DK3689379T3 (da)
EA (1) EA037346B1 (da)
ES (2) ES2789365T3 (da)
GE (2) GEAP202014782A (da)
HR (2) HRP20211599T1 (da)
HU (2) HUE056402T2 (da)
IL (1) IL259327B (da)
MA (1) MA52437A (da)
MX (1) MX377113B (da)
MY (1) MY198321A (da)
PE (1) PE20181377A1 (da)
PH (1) PH12018501023B1 (da)
PL (2) PL3377109T3 (da)
PT (2) PT3689379T (da)
SA (1) SA518391574B1 (da)
SG (2) SG11201804048WA (da)
SI (2) SI3689379T1 (da)
TW (1) TWI729025B (da)
UA (1) UA125173C2 (da)
WO (1) WO2017085007A1 (da)
ZA (1) ZA201803167B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220155609A (ko) * 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
KR20220155395A (ko) 2017-05-11 2022-11-22 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US11304901B2 (en) * 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869B (zh) * 2023-09-27 2026-05-12 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
WO2005004852A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
HUE038555T2 (hu) 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
SI3569222T1 (sl) 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo

Also Published As

Publication number Publication date
PT3689379T (pt) 2021-09-24
AR106687A1 (es) 2018-02-07
HUE050343T2 (hu) 2020-11-30
EP3377109B1 (en) 2020-03-04
HUE056402T2 (hu) 2022-02-28
WO2017085007A1 (en) 2017-05-26
AU2016357988B2 (en) 2021-12-16
MX2018005979A (es) 2018-08-29
US20190021994A1 (en) 2019-01-24
MY198321A (en) 2023-08-24
ES2890409T3 (es) 2022-01-19
EA037346B1 (ru) 2021-03-16
HRP20211599T1 (hr) 2022-01-07
CA3005291C (en) 2024-01-16
US20200360278A1 (en) 2020-11-19
EP3377109A1 (en) 2018-09-26
HRP20200571T1 (hr) 2020-07-10
AU2016357988A1 (en) 2018-05-31
HK1256859A1 (zh) 2019-10-04
US20170136034A1 (en) 2017-05-18
SA518391574B1 (ar) 2021-06-13
ZA201803167B (en) 2019-07-31
US10786451B2 (en) 2020-09-29
UA125173C2 (uk) 2022-01-26
MX377113B (es) 2025-03-07
PL3689379T3 (pl) 2021-12-13
TWI729025B (zh) 2021-06-01
ES2789365T3 (es) 2020-10-26
KR20180082442A (ko) 2018-07-18
NZ742473A (en) 2024-11-29
US10086003B2 (en) 2018-10-02
CN108348614B (zh) 2021-09-21
PL3377109T3 (pl) 2020-09-21
PH12018501023A1 (en) 2018-12-17
GEAP202014782A (en) 2020-04-27
CL2018001297A1 (es) 2018-08-10
GEAP201614782A (da) 2020-04-27
CO2018005139A2 (es) 2018-08-10
SG10201912090UA (en) 2020-02-27
DK3689379T3 (da) 2021-09-06
MA52437A (fr) 2021-05-05
JP6942126B2 (ja) 2021-09-29
EA201890967A1 (ru) 2018-12-28
IL259327A (en) 2018-07-31
PT3377109T (pt) 2020-05-13
US10959944B2 (en) 2021-03-30
PH12018501023B1 (en) 2018-12-17
SI3377109T1 (sl) 2020-07-31
IL259327B (en) 2020-11-30
CA3005291A1 (en) 2017-05-26
BR112018009811A8 (pt) 2019-02-26
EP3689379B1 (en) 2021-08-11
SG11201804048WA (en) 2018-06-28
PE20181377A1 (es) 2018-09-05
TW201722403A (zh) 2017-07-01
CN108348614A (zh) 2018-07-31
GEP20207178B (en) 2020-11-10
BR112018009811A2 (pt) 2018-11-13
EP3689379A1 (en) 2020-08-05
JP2018537453A (ja) 2018-12-20
SI3689379T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
HUE054042T2 (hu) Pirazolvegyületek és eljárás a vegyületek elõállítására és alkalmazásuk
DK3390395T3 (da) Forbindelser, der kan anvendes som kinase-inhibitorer
DK3628331T3 (da) Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum
DK3294720T3 (da) Fremgangsmåde til fremstilling af terpinolenepoxid
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
HUE064612T2 (hu) Eljárás brivaracetam elõállítására
DK3689379T3 (da) Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
DK3383436T3 (da) Forbedret fremgangsmåde til fremstilling af indocyaningrønt
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
PL3256154T3 (pl) Preparat farmaceutyczny zawierający przeciwciało
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3634968T3 (da) Heterocykliske forbindelser, der kan anvendes som antibakterielle midler, og fremgangsmåde til fremstilling heraf
DK3148976T3 (da) Fremgangsmåde til fremstilling af dihydroisoxazolderivater
EP3294703A4 (en) A process for the preparation of verapamil hydrochloride
DK3187280T3 (da) Fremgangsmåde til fremstillingen af en formulering og formulering
DK3328842T3 (da) Fremgangsmåde til fremstillingen af isocarboxazid
TH1601000099A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด
HUE047523T2 (hu) Eljárások indazol-származékok elõállítására